Vinay Prasad has been reinstated as the head of the Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), resuming his role overseeing vaccines, gene therapies, and blood product regulation. This return comes less than two weeks after his abrupt resignation, which followed pressure from conservative allies of former President Donald Trump, biotech executives, and patient groups. Prasad, an oncologist and noted critic of U.S. COVID-19 vaccine and mask mandates, was initially appointed as CBER director in May 2025. His ouster was reportedly influenced by online smears and political opposition, including efforts led by conservative activist Laura Loomer. The FDA's decision to reinstate Prasad has caused uncertainty within the biotech sector, with shares of some companies declining amid the leadership turmoil. The agency has not clarified internal staffing changes related to his return, and the circumstances surrounding the reversal remain complex. Prasad's reinstatement signals a potential shift in FDA leadership dynamics and drug development policies, with observers noting the challenges he faces in balancing scientific nuance and public health priorities.